Literature DB >> 29069649

The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis.

Wenjun Liao1, Hua Zheng, Sha Wu, Yanmei Zhang, Wei Wang, Zili Zhang, Chenfei Zhou, Hongjun Wu, Jie Min.   

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is characterized by abnormal activated T cells, autoreactive B cells, and massive cytokines. The CD4+ T cells determined B-cells differentiation and cytokines production. The programmed death 1 (PD-1) is the checkpoint immunoinhibitory receptor of activated T cells, and its engagement could exhaust T cells. In this study, we investigated the role of PD-1 systemic engagement with PD-L1-Ig in lupus-like nephritis in SLE mice.
METHODS: The murine PD-L1-Ig was injected into SLE-prone mice. The proteinuria and survival ratio were monitored. The production of anti-dsDNA autoantibodies and cytokines in serum were measured by enzyme-linked immunosorbent assay. The cytokine-producing T cells (interferon-γ, IFN-γ and IL-17α) in kidney and spleen were detected with flowcytometry. The pathological evaluation of the Ig deposition in the glomeruliand was determined with immunofluorescence. Lymphocytes in 24-h urine were detected with flowcytometry.
RESULTS: The systemic administration of PD-L1-Ig activated PD-1-PD-L1 axis of CD4+ T lymphocytes, suppressed Th17 formation in many organs, including the spleen and the kidney, demolished abnormal production of cytokines (IFN-γ, IL-17, and IL-10) and anti-dsDNA autoantibodies in serum, inhibited immunoglobulin G deposition in the glomeruli with the decrease of proteinuria, and activated T cells in urine. Accordingly, the systemic conjugation of PD-L1-PD-1 impaired renal autoimmune injure and prolonged survival time.
CONCLUSION: Our research demonstrated that the protective function of systemic activation of PD-1-PD-L1 axis with PD-L1-Ig attenuates the nephritis in SLE-prone mice, which facilitates us to understand the suppressive function of PD-1-PD-L1 axis in the pathogenesis and progress of the lupus nephritis, and to explore a possible effective therapeutic strategy to SLE.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Immunotherapy; Lupus nephritis; PD-L1

Mesh:

Substances:

Year:  2017        PMID: 29069649     DOI: 10.1159/000480641

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  7 in total

Review 1.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

Review 2.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

Review 3.  Checkpoint Molecules in Rheumatology-or the Benefits of Being Exhausted.

Authors:  Stinne Ravn Greisen; Bent Deleuran
Journal:  Curr Rheumatol Rep       Date:  2021-03-02       Impact factor: 4.592

4.  Activation of PD-1 Protects Intestinal Immune Defense Through IL-10/miR-155 Pathway After Intestinal Ischemia Reperfusion.

Authors:  Xu-Yu Zhang; Su Guan; Hu-Fei Zhang; Rui-Yun Li; Zi-Meng Liu
Journal:  Dig Dis Sci       Date:  2018-09-12       Impact factor: 3.199

5.  Long Noncoding RNA Hotair Promotes the Progression and Immune Escape in Laryngeal Squamous Cell Carcinoma through MicroRNA-30a/GRP78/PD-L1 Axis.

Authors:  Xiaowei Yuan; Qinhua Shen; Wenxue Ma
Journal:  J Immunol Res       Date:  2022-04-04       Impact factor: 4.818

Review 6.  Immune regulation in renal inflammation.

Authors:  Katrin Neumann; Gisa Tiegs
Journal:  Cell Tissue Res       Date:  2021-01-26       Impact factor: 4.051

7.  Immune Checkpoint Inhibitors' Associated Renal Toxicity: A Series of 12 Cases.

Authors:  Kostas Palamaris; Dimitrios Alexandris; Kostas Stylianou; Ioannis Giatras; Anastasios Stofas; Christina Kaitatzoglou; Magda Migkou; Dimitrios Goutas; Erasmia Psimenou; Eleni Theodoropoulou; Stamatios Theocharis; Nektarios Alevizopoulos; Efstathios Kastritis; Alexandros Gerakis; Harikleia Gakiopoulou
Journal:  J Clin Med       Date:  2022-08-16       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.